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CLINICAL ARTICLE
Delay in Diagnosis and Its Effect on Clinical
Outcome in High-grade Sarcoma of Bone:
A Referral Oncological Centre Study
Louren M Goedhart, MD, Jasper G Gerbers, MD, PhD, Joris J W Ploegmakers, MD, Paul C Jutte, MD, PhD
Department of Orthopaedics, University Medical Center, University of Groningen, Groningen, The Netherlands
Objective: To investigate delay in diagnosis by both patients and doctors, and to evaluate its effect on outcomes of
high-grade sarcoma of bone in a single-referral oncological center.
Methods: Fifty-four patients with osteosarcoma, 29 with Ewing sarcoma and 19 with chondrosarcoma were enrolled
in this retrospective study. Delay in diagnosis was defined as the period between initial clinical symptoms and histo-
pathological diagnosis at our center. The delays were categorized as patient- or doctor-related. Short total delays were
defined as <4 months; prolonged delays >4 months were assumed to have prognostic relevance.
Results: Total delay in diagnosis was 688.0 days in patients with chondrosarcoma, which is significantly longer than
the 163.3 days for osteosarcoma (P < 0.01) and 160.2 days for Ewing sarcoma (P < 0.01). Most doctor-related
delays were at the pre-hospital stage, occurring at the general practitioner (GP)’s office. However, prolonged total
delays (≥4 months) did not result in lower survival rates. Five-year-overall survival rates were 67.0% for osteosarcoma,
49.0% for Ewing sarcoma and 60.9% for chondrosarcoma. Survival was significantly lower for patients with metastatic
disease for all three types of sarcoma.
Conclusion: Prolonged delay in diagnosis does not result in lower survival. Metastatic disease has a pronounced
effect on survival. Aggressive tumor behavior results in shorter delays. Minimizing GP-related delays could be achieved
by adopting a lower threshold for obtaining plain radiographs at the pre-hospital stage.
Key words: Doctor-related delay; Patient-related delay; Sarcoma; Survival
Introduction
High-grade primary bone sarcomas are rare and aggres-sively invade soft tissue from bone. The most common
high-grade bone sarcomas are osteosarcoma, Ewing sarcoma
and chondrosarcoma. Because of their malignant nature and
ability to metastasize, aggressive treatment is required1. The
introduction of chemotherapy has dramatically improved
survival of individuals with osteosarcoma and Ewing
sarcoma2–6. While surgical and medical treatment options
have also evolved since then, there has been no further
remarkable improvement in survival rates7–9. Early diagnosis
and treatment are still vital because local control is easier
and may help prevent metastasis. Metastasis of high-grade
sarcomas of bone greatly impacts survival10,11. A cooperative
group of oncologists in the Netherlands, Stichting Oncolo-
gische Samenwerking (SONCOS), has issued a general guide-
line on timely diagnosis of cancer. Diagnosing bone tumors
is notoriously difficult and sometimes time-consuming, as in
most cases multidisciplinary diagnosis by local or nationwide
musculoskeletal tumor committees like the Dutch Commit-
tee on Bone Tumors is necessary. Hence, in some cases it is
impossible to meet these guidelines.
Only a few series regarding delay in diagnosis have
been published12–16. Prolonged duration of symptoms is
associated with larger tumor size and increased rate of
metastasis, but not with inferior outcomes12,17. Reducing
patients’ associated delay seems difficult because of the low
incidence of these diseases. Most general practitioner s (GPs)
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will only encounter a primary bone sarcoma a few times dur-
ing their entire career, even though they deal with musculo-
skeletal complaints daily. Kim et al. demonstrated that
doctor-related delays followed by inappropriate primary pro-
cedures significantly influence survival18. A detailed analysis
of diagnostic delays may reveal new insights on how to
improve awareness among patients and physicians.
The University Medical Center Groningen (UMCG),
one of four accredited bone tumor centers in the Nether-
lands, provides regional coverage for the treatment of bone
sarcomas, as shown in Fig. 1. In this study, we quantified
and analyzed patient- and doctor-related delays and their
effects on clinical outcomes in a large series of high-grade
bone sarcomas with the aim of identifying new strategies for
shortening delays.
Material and Methods
All cases were selected from a prospectively maintainedbone tumor registry at UMCG. A minimum follow-up
of 12 months was an inclusion criterion. All 102 consecutive
patients with high-grade bone sarcoma diagnosed between
October 2000 and October 2012 were included. They com-
prised 54 patients with osteosarcoma, 29 with Ewing sar-
coma and 19 with intermediate or high-grade
chondrosarcoma.
Delays in diagnosis were calculated in days and cate-
gorized as patient-related or doctor-related. Patient-related
delays were defined as the period between the initial symp-
tom and first consultation with a GP, which is required for
all Dutch patients prior to referral to a specialized service.
GPs were asked to provide the date of the first entry in their
medical records concerning tumor-related symptoms (swell-
ing, daytime/night-time pain, loss of function, etc.). Doctor-
related delays were further subdivided as follows: (i) between
presentation to the GP’s office and presentation to a primary
hospital, defined as pre-hospital doctor-related delay;
(ii) between presentation at a primary hospital and an oncol-
ogy center, defined as primary clinic doctor-related delay;
and (iii) between presentation to an oncology center and
definitive histopathological diagnosis, defined as referral
clinic doctor-related delay. The third group was further sub-
divided into two subgroups, ≤42 days and >42 days, accord-
ing to the SONCOS guidelines. The date of presentation at
each general primary hospital was obtained from the referral
letters. When these were not available, the hospital was con-
tacted with a request for the date of first presentation. Not
every patient had been referred to a general secondary hospi-
tal; some had been referred directly to an oncology (referral)
center or had presented to an emergency room. Short total
delays were defined as <4 months; total delays longer than
4 months were assumed to have prognostic relevance based
on expert opinion.
Local presenting symptoms comprised pain, swelling,
pathological fracture and/or loss of function. The presence of
systemic symptoms (fatigue, loss of appetite, weight loss or
fever) was recorded separately.
The primary outcome measure was the effect of delay
(patient- or doctor-related) on oncological outcomes. The
secondary aims were to assess patients’ symptoms in and
determine whether outcomes were is affected by transgres-
sion of the 6-week rule. Statistical analysis was performed
using SPSS statistics 20 for Windows. Normality was tested
using the Shapiro–Wilk test. Survival analysis was performed
separately for each pathological type of sarcoma using
Kaplan–Meier survival curves. The impact of delay in diag-
nosis on joint salvage rate and local recurrence was also
investigated using binary logistic regression analysis.
Results
In all, 102 patients, 57 of whom were male and 45 female,were enrolled in this study. The mean age at presentation
was 30.0 years (range, 5–89 years). The subjects were cate-
gorized according to pathological diagnosis: 54 had osteosar-
comas, 29 Ewing sarcoma and 19 chondrosarcoma.
Clinicopathological characteristics according to pathological
diagnosis are shown in Table 1.
Fig. 1 Regional coverage for the treatment of bone sarcomas in the
Netherlands. The capital of the Netherlands, Amsterdam, is marked in
blue and the city of Groningen in red. The University Medical Center
Groningen is located in Groningen and provides regional coverage,
being the oncology center for the treatment of bone sarcomas in the




VOLUME 8 • NUMBER 2 • MAY, 2016
DIAGNOSTIC DELAY HIGH-GRADE BONE SARCOMA
Clinical Characteristics
Osteosarcomas were located in the long bones in 50 patients
(92.6%), the femur being the predominant site (31 patients,
57.4%). Pain was the most frequent symptom, being present
in 44 patients (81.4%). Most Ewing sarcomas were located in
the axial skeleton (18 patients, 62.1%) with the spine or ribs
as the predominant site in nine patients (31.0%), followed by
the pelvis in eight patients (27.6%). Ten patients (34.5%)
presented with Ewing sarcoma in their long bones. Pain was
the commonest symptom, being present in 20 patients
(68.9%). Chondrosarcomas were most in the long bones
(eight patients, 42.1%); the most frequent symptom was pain,
which was present in 13 patients (68.4%). Six patients (11%)
with osteosarcoma and 10 (34.5%) with Ewing sarcoma pre-
sented with systemic symptoms, whereas were none of the
patients with chondrosarcoma had systemic symptoms.
Delays in Diagnosis
The mean delay in diagnosis is shown in Table 2 and Fig. 2.
The mean total delay was 163.3 days (standard deviation
[SD], 176.5 days) in patients with osteosarcoma, 160.2 days
(SD, 193.7 days) in patients with Ewing sarcoma, and
688.0 days (SD, 678.4 days) in patients with chondrosar-
coma, this mean total delay being significantly longer than
that for osteosarcoma and Ewing sarcoma (P < 0.01). The
mean patient-related delay for all types of sarcoma was
83.2 days (SD, 208.1 days), being 244.1 days for chondrosar-
coma, which is somewhat longer than that for osteosarcoma
(44.8 days, P = 0.058) and significantly longer than that for
Ewing sarcoma (41.0 days, P = 0.034).
The mean overall doctor-related delay was 156.2 days
(SD, 210.9 days). Mean doctor-related delay for chondrosar-
coma was 332.3 days, which is significantly longer than for
osteosarcoma (100.0 days, P ≤ 0.01) and Ewing sarcoma
(130.6 days, P < 0.01). Mean overall pre-hospital doctor-
related delay was 101.5 days (SD, 189.7 days); data on this
were unavailable for 14 cases (13.5%). The mean overall pri-
mary clinic doctor-related delay was 23.5 days (SD,
30.4 days), data being unavailable for 3.9% of cases. This
delay was significantly longer for patients with chondrosar-
coma (49.7 days) than for those with osteosarcoma
(16.5 days; P < 0.01) or Ewing sarcoma (16.3 days;
P < 0.01). The mean overall referral clinic doctor-related
delay was 27.6 days (SD, 29.6 days), all data being available.
Outcomes
Metastatic disease was present at diagnosis in 24.1% of
patients with osteosarcoma, 37.9% with Ewing sarcoma and
10.5% with chondrosarcoma. Surgical resection of the pri-
mary tumor was performed in 92.4% of patients with osteo-
sarcoma and 55.2% with Ewing sarcoma; all patients with
chondrosarcoma underwent surgical resection. There was no
TABLE 1 Clinicopathological characteristics according to sarcoma type
Characteristic Osteosarcoma (n = 54) Ewing sarcoma (n = 29) Chondrosarcoma (n = 19)
Age at primary therapy (years, mean [range]) 28.9 (8–86) 17.4 (5–56) 52.4 (21–89)
Sex (cases [%])
Male 30 (55.6) 19 (65.5) 8 (42.1)
Female 24 (44.4) 10 (34.5) 11 (57.9)
Location (cases [%])
Long bones 50 (92.6) 10 (34.5) 8 (42.1)
Axial skeleton 4 (7.4) 18 (62.1) 7 (36.8)
Other — 1 (3.4) 4 (21.1)
Primary therapy (cases [%])
Surgical excision 50 (92.6) 16 (55.2) 19 (100)
Chemotherapy/radiotherapy 4 (7.4) 13 (44.8) —
Wide excision (cases [%]) 46 (92.0) 9 (56.3) 16 (84.2)
Additional therapy (cases [%])
(Neo-) adjuvant chemotherapy 44 (81.5) 27 (93.1) —
Radiotherapy 10 (18.5) 22 (75.9) 3 (15.8)
Status after primary therapy (cases [%])
Disease-free 37 (68.5) 15 (51.7) 15 (78.9)
Non-radical resection 3 (5.6) 3 (10.3) 2 (10.5)
Unresectable lesion 1 (1.9) — —
Metastatic disease 13 (24.1) 11 (37.9) 2 (10.5)
Follow-up (months, mean [SD]) 54.9 (42.8) 39.2 (31.2) 54.6 (35.8)
Current status (cases [%])
Continuously disease-free 24 (44.4) 11 (37.9) 10 (52.6)
Alive with disease 2 (3.7) 1 (3.4) 1 (5.3)
No evidence of disease 8 (14.8) 4 (13.8) 1 (5.3)
Dead of disease 18 (33.3) 13 (44.8) 6 (31.6)
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association between length of delay and rate of limb salvage
procedures. Overall, 16 patients with tumors in the axial
skeleton underwent surgical excision, resulting in intrale-
sional resections in 43.8% of them, compared with 9.4% of
60 patients with tumors in the long bones (P < 0.01). Adju-
vant chemotherapy was given to 93.7% of patients with
Ewing sarcoma. Local recurrence was diagnosed in
16 patients (15.7%), six of whom had osteosarcomas (11.1%),
five Ewing sarcomas (17.2%) and five chondrosarcomas
(26.3%). There was no association between length of delay
and local recurrence rate for any single pathological type or
overall. At the end of follow-up, 44.4% of patients with oste-
osarcoma, 37.9% with Ewing sarcoma and 52.6% with chon-
drosarcoma were continuously disease-free. After primary
treatment, no evidence of disease was seen in 14.8% of sub-
jects with osteosarcoma, 13.8% of those with Ewing sarcoma
and 5.3% of those with chondrosarcoma. Patient mortality
was highest for Ewing sarcoma; 44.8% of cases dying of
disease.
Survival
Thirty-eight patients (37.3%) had a minimum follow-up of
5 years. The mean duration of follow-up in patients with
osteosarcoma was 54.9 months (SD, 42.8 months) with a 5-
year overall survival rate (60 months) of 67.0% (SD,
6.6 months). The mean duration of follow-up in patients
with Ewing sarcoma was 39.2 months (SD, 31.2 months)
with a 5-year overall survival rate (62 months) of 49.0% (SD,
11.1 months). The mean duration of follow-up in patients
with chondrosarcoma was 54.6 months (SD, 35.8 months)
with a 5-year overall survival rate (61 months) of 60.9% (SD,
13.0 months). Five-year overall survival curves are displayed
in Fig. 3.
TABLE 2 Delay in diagnosis (days, mean [standard deviation]) according to sarcoma type
Mean delay in days Osteosarcoma (n = 54) Ewing sarcoma (n = 29) Chondrosarcoma (n = 19)
Total delay 163.3 (176.5) 160.2 (193.7) 688.0 (678.4)*
Patient-related delay 44.8 (41.8) 41.0 (40.5) 244.1 (433.5)*
Mean doctor-related delay 100.0 (94.6) 130.6 (217.6) 332.3 (312.7)*
Pre-hospital doctor-related delay 57.8 (56.1) 103.6 (223.8) 197.2 (291.9)
Primary clinic doctor-related delay 16.5 (21.3) 16.3 (21.3) 49.7 (43.6)*
Referral clinic doctor-related delay 26.6 (28.2) 24.5 (28.0) 34.9 (36.0)
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Overall (all sarcoma types), 5-year-overall survival
rates were significantly lower for patients with tumors in the
axial skeleton (46.0%) than for those with long bone tumors
(72.3%; P = 0.016). In patients with osteosarcoma, the 5-
year-overall survival was significantly lower for tumors in the
axial skeleton (25.0%) than for those in long bones (71.0%;
P = 0.026). For Ewing sarcoma and chondrosarcoma, tumor
location did not significantly impact 5-year-overall survival.
The 5-year-overall survival of patients with osteosar-
coma was significantly lower after intralesional re-
section (25.0%) than after wide resection (77.3%; P = 0.01).
Similarly, for Ewing sarcoma, the 5-year-overall survival was
significantly lower after intralesional resection (42.9%) than
after wide resection (71.1%; P = 0.048). The excision margin
did not significantly impact 5-year-overall survival in sub-
jects with chondrosarcoma.
Five-year-overall survival rates were significantly lower
in patients with metastatic osteosarcoma (26.9%) than in
patients who remained disease-free after resection (79.3%;
P < 0.01). Survival of subjects with metastatic Ewing sarcoma
was also significantly lower (36.4%) than for disease-free
patients (72.7% after 62 months; P < 0.01). The 5-year over-
all survival rates of patients with chondrosarcoma and
metastases was 50% compared 69.5% in patients who
remained disease-free (P < 0.01).
The mean overall delay from presentation at UMCG to
histological diagnosis for each sarcoma type was compared
based on the SONCOS guidelines and it was found that the
5-year overall survival rate for osteosarcoma diagnosed in
<42 days was 58.2%, as against 76.9% in patients diagnosed
≥42 days (not significant [NS]). The overall survival rate
after 62 months for patients with Ewing sarcoma diagnosed
in <42 days was 39.4%, compared to 80.0% of patients diag-
nosed ≥42 days (NS). The overall survival after 61 months
for chondrosarcoma was 46.2% in patients diagnosed in
<42 days and 83.3% in patients diagnosed ≥42 days (NS).
There were no significant differences in 5-year overall
survival rates between total delay <4 months and a longer
total delay for patients with osteosarcoma and Ewing sar-
coma. There was no significant difference in overall survival
rates between a total delay <4 months (two patients, 50%
overall survival after 40 months) and a delay ≥4 months
(17 patients, 63.6% overall survival after 61 months) for
patients with chondrosarcoma. No significant differences
were identified in metastatic disease rates after a total delay
<4 months compared to a longer total delay for any of the
three pathological types or for all subjects combined.
Discussion
Delay in diagnosis may have an adverse effect on onco-logic outcomes. SONCOS guidelines state that diagnosis
at an oncology center within 42 days minimizes negative
effects on outcome. The purpose of this study was to investi-
gate patient- and doctor-related delays and evaluate their
effects on outcomes. High-grade bone sarcomas are rare neo-
plasms; 102 lesions were seen in our referral oncology center
over 12 years. The present study provides a valuable addition
to data of other published Dutch series on outcomes of high-
grade bone sarcomas19–22. Furthermore, this report includes
8.3% of all patients with high-grade bone sarcomas who
underwent orthopaedic oncological treatment in the Nether-
lands during that 12 years23. Because our study focused on
the effect of delay in diagnosis, one of its limitations is that
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Fig. 3 Five-year-overall survival for high-grade
sarcoma of bone according to sarcoma type.
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There are few relevant published reports, as shown in
Table 3. Bacci et al. reported a shorter delay in patients with
metastatic osteosarcomas than in those with localized dis-
ease12. They concluded that aggressive tumor behavior
results in shorter delays. This conclusion is in accordance
with our results, since patients with chondrosarcoma had
significantly longer delays in diagnosis than those with osteo-
sarcoma and Ewing sarcoma. However, the long delay in
diagnosis of intermediate and high-grade chondrosarcoma
did not result in lower survival rates. We believe that this
can be explained by less aggressive tumor behavior, absence
of systemic symptoms and the inclusion of intermediate-
grade chondrosarcomas. However, it is important to recog-
nize that chondrosarcoma can dedifferentiate and that this is
associated with poor survival.
Sneppen and Hansen defined treatment delay as the
time from the first symptom until presentation at an oncol-
ogy center14. Their mean treatment delay was 6.4 months for
osteosarcoma and 9.6 months for Ewing sarcoma, which is
longer than our series, in which there was a treatment delay
of 3.9 months for osteosarcoma and 5.3 months for Ewing
sarcoma. Comparison between the Bacci study and our own
is difficult because referral patterns and accuracy have
evolved over the past 30 years.
Primary orthopaedic hospitals in the Netherlands fol-
low the guidelines on bone tumors, which specify that biopsy
and treatment should be performed in an oncology referral
center. Although diagnostic delay at an oncology center
makes up only a small slice of the total delay, it is the most
visible type of delay. According to SONCOS, the acceptable
referral clinic doctor-related delay for a Dutch oncological
center to diagnose a neoplasm and start treatment is
42 days27. In this study, the referral clinic doctor-related
delay from presentation to diagnosis was 27.6 days and thus
within our national standards. For high-grade chondrosar-
coma it was 34.9 days. Because these tumors often present in
the pelvis and may therefore be difficult to access for biopsy,
multiple biopsies may be performed before a definitive diag-
nosis is made. Delay in diagnosis is also associated with
other clinical variables; Kim et al. found that misdiagnosis
and inappropriate treatment resulted in inferior outcomes in
subjects with osteosarcoma18. This is in accordance with our
study, in which we found significantly lower survival rates in
patients with osteosarcoma and Ewing sarcoma after intrale-
sional surgical resection. Furthermore, intralesional surgical
resection occurred more often with tumors located in the
axial skeleton. Location of a tumor in the axial skeleton is
also associated with lower survival rates.
According to our data, diagnosis after 42 days of high-
grade bone sarcomas does not result in lower survival;
neither do total delays exceeding 4 months. And yet, para-
doxically, metastatic disease after primary resection is associ-
ated with significantly lower survival rates. This discrepancy
may be explained by the fact that aggressive tumor behavior
results in early clinical symptoms, thereby facilitating a
timely diagnosis. Our findings imply that tumor location and
resectability have more influence on survival than delay in
diagnosis in patients with osteosarcoma and Ewing sarcoma.
Tumor location and resectability, metastatic disease at
diagnosis, response to chemotherapy and local recurrence
are known prognostic factors for osteosarcoma and Ewing
sarcoma according to published reports8,26,28–34.
Most of the diagnostic delay occurred in the pre-
hospital setting at the GP’s office. We realize that is very
difficult for GPs to recognize a bone malignancy because
they generally only encounter one or two primary bone sar-
comas in their entire careers. Pain was the most common
symptom in our study and in other reports14,15. Therefore
GPs should have a low-threshold for requesting plain radio-
graphs in patients with pain and no history of trauma; such
a policy would likely decrease mean doctor-related delay by
accelerating referral to an oncology center. Persistent pain
for more than 6 weeks is a red flag and an indication for a
radiograph.
In conclusion, this study provides valuable insight into
diagnostic delay patterns for high-grade bone sarcomas in
the Netherlands. Prolonged delay in diagnosis of high-grade
sarcomas of the bone does not result in lower survival. The
SONCOS guidelines for diagnosing neoplasms are easily met,
but do not seem clinically relevant to high-grade bone sarco-
mas. Persistent pain for more than 6 weeks in the pre-
hospital (GP) setting is an indication for a radiograph.
TABLE 3 Relevant published reports on delay in diagnosis of high-grade bone sarcomas
Authors Years Sarcoma type Conclusion
Sneppen and Hansen14 1984 84 osteosarcomas
40 Ewing sarcomas
No association between delay and survival
Wurtz et al.25 1999 68 pelvic chondrosarcomas No association between delay and survival
Widhe and Widhe15 2000 102 osteosarcomas
47 Ewing sarcomas
Doctor-related delay significantly longer for Ewing sarcoma
Bacci et al.26 2000 965 high-grade osteosarcomas Aggressive tumor behavior results in shorter delay
Kim et al.18 2009 26 osteosarcomas Doctor-related delay superimposed on an inappropriate primary
procedure has a detrimental effect on survival
Pan et al.13 2010 30 knee-region osteosarcomas Total delay in diagnosis 17 weeks
Goedhart et al. (current study) 2016 54 osteosarcomas
29 Ewing sarcomas
19 chondrosarcomas
Longer delay in patients with chondrosarcoma, no effect on outcome
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